{
    "pmcid": "8181738",
    "qa_pairs": {
        "How can bioinformatic tools aid in the design of nanobody binders for the spike protein?": [
            "By visualizing and analyzing the spike protein structure",
            "By predicting the spike protein's mutation rate",
            "By simulating the spike protein's interaction with host cells",
            "By enhancing the spike protein's immune recognition"
        ],
        "What advantage do nanobodies have over conventional antibodies in targeting the spike protein?": [
            "Their small size allows them to bind less accessible epitopes",
            "They can induce stronger immune responses",
            "They are less expensive to produce",
            "They have a longer half-life in the bloodstream"
        ],
        "What is a significant challenge posed by the glycosylation of the spike protein?": [
            "It can mask epitopes and hinder antibody binding",
            "It increases the spike protein's binding affinity to ACE2",
            "It enhances the spike protein's structural stability",
            "It reduces the spike protein's ability to mutate"
        ],
        "What is the primary role of the S1 subunit of the SARS-CoV-2 spike protein?": [
            "Responsible for receptor binding",
            "Facilitates membrane fusion",
            "Undergoes glycosylation",
            "Increases viral transmissibility"
        ],
        "Which mutation in the spike protein is associated with increased viral transmissibility?": [
            "D614G",
            "N501Y",
            "E484K",
            "K417N/T"
        ]
    }
}